Drug intelligence / Profile preview

ALAM108

Development stage: Preclinical
Lead developer: AL&AM Pharmachem
Modality: Small Molecules
Administration: Oral

Overview

ALAM108 is a synthetic derivative of tetrahydrocannabinolic acid (THCA) being investigated for the treatment of pancreatic cancer. Developed by Alamedic, the compound has demonstrated potent in vitro activity against PANC-1 and AsPC-1 pancreatic cancer cell lines. In preclinical xenograft models, oral administration of ALAM108 significantly reduced tumor volume and weight without causing significant weight loss or discomfort in mice. It is part of a series of cannabinoid derivatives designed to leverage the anti-tumor properties of cannabinoids while potentially optimizing pharmacokinetic profiles for oral delivery.

Other names: tetrahydrocannabinolic acid derivative ALAM108

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on ALAM108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALAM108.

Explore the full profile